Copenhagen, Denmark—Updated results from the Phase IIb LUX-Lung 7 trial of afatinib versus gefitinib were presented at the European Society for Medical Oncology (ESMO) 2016 Congress showing a nonsignificant trend for an overall survival (OS) benefit for afatinib (abstract LBA43).
In earlier data from this trial, which was the first to compare tyrosine kinase inhibitors (TKIs) head-to-head for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), afatinib